Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/127587
Title: Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials
Authors: Giuliani, Jacopo 
Bonetti, Andrea
Keywords: Advanced NSCLC;Costs of drugs;First-line chemotherapy;Randomized phase III trials;Targeted therapies
Keywords Plus: OPEN-LABEL;PROGRESSION-FREE;EGFR MUTATIONS;ADENOCARCINOMA;CHEMOTHERAPY;MULTICENTER;GEMCITABINE;GEFITINIB;ERLOTINIB;SURVIVAL
Mesh headings: Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Non-Small-Cell Lung;Drug Costs;ErbB Receptors;Protein Kinase Inhibitors
Secondary Mesh headings: Clinical Trials, Phase III as Topic;Cost-Benefit Analysis;Humans;Molecular Targeted Therapy;Mutation;Neoplasm Staging;Randomized Controlled Trials as Topic
Issue Date: Mar-2016
Publisher: CIG MEDIA GROUP, LP
Journal: Clinical lung cancer 
URI: http://hdl.handle.net/20.500.12857/127587
ISSN: 15257304
DOI: 10.1016/j.cllc.2015.12.005
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

2
Last Week
0
Last month
checked on Aug 8, 2021

SCOPUSTM   
Citations 5

2
checked on Aug 31, 2020

WEB OF SCIENCETM
Citations

3
checked on Nov 24, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.